
March 2 (Reuters) - Bioxytran Inc BIXT.PK:
BIOXYTRAN INC: REPORTS POSITIVE PHASE 1B/2A CLINICAL STUDY RESULTS FOR PROLECTIN-M, BROAD-RANGE ANTIVIRAL DRUG IN MILD TO MODERATE COVID-19
BIOXYTRAN INC - NO SERIOUS ADVERSE EVENTS REPORTED, NO TREATMENT-RELATED DISCONTINUATIONS OCCURRED- SEC FILING
BIOXYTRAN INC - PROLECTIN-M WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS - SEC FILING
Source text: []